FDA Takes Cue From Nordic Countries On Moderna Vaccine

Nordic nations have outright banned Moderna’s shot.

They cited concerns with side effects, and potential long-term health implications of the vaccine— Moderna has also had to recall large batches of shots in Japan due to contaminants.

Now our own FDA is taking a cue from these Nordic countries, by delaying the Moderna shot for adolescents.

Personally, I don’t think this is enough, and we should do what Sweden and Iceland have done and outright ban the Moderna shot, but at least U.S. authorities are somewhat paying attention.

Here are the latest developments:

FDA is delaying its decision on authorizing Moderna's COVID-19 vaccine for teens aged 12-17 'due to reports of side effects' https://t.co/Tep2QRSFeN

— Daily Mail US (@DailyMail) October 15, 2021

From today's #WSJ by Felicia Schwartz The FDA is delaying a decision on authorizing Moderna Inc.’s Covid-19 vaccine for ADOLESCENTS to assess whether the shot may lead to a heightened risk of a rare inflammatory heart condition, according to people familiar with the matter.

— Tom Wall (@pindergast) October 16, 2021

Just The News quotes The Wall Street Journal article:

“The FDA has been taking another look at the risk of the condition, known as myocarditis, among younger men who took Moderna’s vaccine,” especially compared to those who received other brands of the vaccine.”

Finally something sensible, but they are still #lying about everything else.

FDA is delaying a decision on authorizing Moderna’s Covid-19 vaccine for adolescents to assess whether the shot may lead to heightened risk of a rare heart condition https://t.co/tWRA6d82cV via @WSJ

— drugbunny (@drugbunnytwit) October 16, 2021

"FDA delays Moderna for adolescents to review rare side effect" #biznews #businessnews #businesstalk The Food and Drug Administration is delaying a decision on authorizing Moderna Inc.’s MRNA -1.69% COVID-19 vaccine for adolescents to assess whether the shot may lead to heig… pic.twitter.com/3WM5Iwvr8L

— Business News Daily (@biznews_daily) October 16, 2021

Newsmax reports:

Moderna’s shares fell nearly 2% to $326.25 in midday trading after the report.

The agency has not yet determined whether there is heightened risk, the report added.

Earlier this month, Finland, Sweden and Denmark paused the use of Moderna’s COVID-19 shot for younger males due to reports of the side effect, myocarditis, in men.